Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Operating Expenses (2021 - 2025)

Verrica Pharmaceuticals has reported Operating Expenses over the past 5 years, most recently at $12.3 million for Q4 2025.

  • Quarterly results put Operating Expenses at $12.3 million for Q4 2025, up 4.51% from a year ago — trailing twelve months through Dec 2025 was $47.8 million (down 35.0% YoY), and the annual figure for FY2025 was $47.8 million, down 35.0%.
  • Operating Expenses for Q4 2025 was $12.3 million at Verrica Pharmaceuticals, down from $12.7 million in the prior quarter.
  • Over the last five years, Operating Expenses for VRCA hit a ceiling of $26.8 million in Q3 2023 and a floor of $6.3 million in Q4 2022.
  • Median Operating Expenses over the past 5 years was $11.8 million (2021), compared with a mean of $13.3 million.
  • Biggest five-year swings in Operating Expenses: skyrocketed 300.13% in 2023 and later plummeted 53.22% in 2024.
  • Verrica Pharmaceuticals' Operating Expenses stood at $8.5 million in 2021, then dropped by 25.87% to $6.3 million in 2022, then skyrocketed by 300.13% to $25.1 million in 2023, then tumbled by 53.22% to $11.8 million in 2024, then grew by 4.51% to $12.3 million in 2025.
  • The last three reported values for Operating Expenses were $12.3 million (Q4 2025), $12.7 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.